A new look at the ALK gene in cancer: copy number gain and amplification
EXPERT REVIEW OF ANTICANCER THERAPY(2016)
摘要
To date, ALK-rearrangement is a molecular target in several cancers, i.e. NSCLC. The dramatic benefits of crizotinib have prompted research into identifying other possible patients carrying ALK gene alterations with possible clinical significance. The ALK gene is involved not only in several rearrangements but also in other alterations such as amplification. ALK-amplification (ALK-A) is a common genetic event in several cancers, generally associated with poor outcome and more aggressive behaviour. Here we review the role of ALK-A in cancer as a prognostic and predictive biomarker. Furthermore, several critical issues regarding ALK-A in relation to; methods of detection, acquired resistance and ALK second generation inhibitors are analyzed. We conclude that ALK-A could be an intriguing alteration in the context of targeted therapy.
更多查看译文
关键词
Anaplastic lymphoma kinase,amplification,copy number gain,fluorescence in situ hybridization,crizotinib,ALK- inhibitors,acquired resistance
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络